FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207681820> ?p ?o ?g. }

• W3207681820 endingPage "S1091" @default.
• W3207681820 startingPage "S1090" @default.
• W3207681820 abstract "ROS1-rearranged non-small cell lung cancer (NSCLC), present in 1-2% of diagnoses, is a genetically distinct type of NSCLC which can be successfully managed through the use of targeted therapy, specifically the first-generation ALK-inhibitor, crizotinib, which doubles as highly effective inhibitor of aberrant ROS1 activity. Clinical trials have shown crizotinib to be safe and effective; however, the use of crizotinib and its safety and efficacy in real-world ROS1-rearranged populations requires further exploration. Consequently, this study initiated a retrospective, observational, population-based investigation into the safety and efficacy of crizotinib in ROS1-rearranged NSCLC patients diagnosed and treated in Alberta, Canada. Alberta patients with advanced or metastatic ROS1-rearranged NSCLC, receiving crizotinib as their first targeted ROS1-inhibitor between January 2014 and June 2020 were identified. Demographic, clinical, treatment and outcome data were extracted from the institutional Glans-Look Lung Cancer Research Database. 21 ROS1-rearranged crizotinib-treated patients were identified: median age was 51.6 years, 67% female, 86% never-smokers. 96% had metastatic disease at crizotinib initiation (38% M1c stage), 67% ECOG < 2, and 57% of patients had previous exposure to systemic chemotherapy (including platin-pemetrexed) and/or immunotherapy. 38% of patients were alive, 29% with crizotinib therapy ongoing, at the time of analysis. One-year survival was 47% following crizotinib initiation; median OS and PFS were 33.3 and 10.6 months, respectively. Disease control rate was 62%, while 14% showed primary resistance to crizotinib. ECOG was not significantly associated with outcome or clinical response. Adverse events (AE) were reported in 52% of patients, most common were gastrointestinal (29%) or investigational disorders (14%), and primarily grade 1 or 2. 19% of patients experienced grade 3+ AE and subsequently terminated crizotinib. Treatment breaks +/- dose modifications occurred in 16%. Patients remained on crizotinib for a median 6.9 cycles before discontinuation. Progressive disease was the most common reason for crizotinib termination (40% of crizotinib discontinuations); upon termination 24% received additional systemic treatment (range 1-3), all receiving additional ROS1-inhibitors. 33% of crizotinib terminations were due to death. 29% of patients had brain metastases at crizotinib initiation and 14% developed brain metastases while on crizotinib, predominantly managed with radiotherapy (67%). Presence/absence of brain metastasis did not significantly impact outcome, but baseline brain metastases resulted in a shorter duration of use and lower rate of clinical response to crizotinib. 48% had high PD-L1 expression (>50%) and 29% received immunotherapy (all prior to crizotinib initiation), with mPFS of 10.1 weeks and DCR of 33%. PD-L1 expression nor immunotherapy use had a significant impact on survival. This real-world study suggests crizotinib therapy for ROS1-rearranged NSCLC in a Canadian clinical setting is an effective, safe and tolerable therapy; however, this real-world cohort was unable to completely meet the outcomes found in crizotinib-treated ROS1-rearranged clinical trial cohorts. As a real-world population, lack of ROS1 testing, delayed access to crizotinib and heavy pre-treatment resulted in high disease burden and early failures on crizotinib, likely impacting crizotinib efficacy. This reinforces the need for real-world data alongside clinical trial data and highlights the need for expeditious access to appropriate targeted therapies in this population." @default.
• W3207681820 created "2021-10-25" @default.
• W3207681820 creator A5020652394 @default.
• W3207681820 creator A5043640511 @default.
• W3207681820 creator A5049060308 @default.
• W3207681820 creator A5078451650 @default.
• W3207681820 date "2021-10-01" @default.
• W3207681820 modified "2023-10-04" @default.
• W3207681820 title "P45.13 Efficacy and Safety of Crizotinib in Real-World ROS1-rearranged NSCLC: A Retrospective Canadian Cohort" @default.
• W3207681820 doi "https://doi.org/10.1016/j.jtho.2021.08.481" @default.
• W3207681820 hasPublicationYear "2021" @default.
• W3207681820 type Work @default.
• W3207681820 sameAs 3207681820 @default.
• W3207681820 citedByCount "0" @default.
• W3207681820 crossrefType "journal-article" @default.
• W3207681820 hasAuthorship W3207681820A5020652394 @default.
• W3207681820 hasAuthorship W3207681820A5043640511 @default.
• W3207681820 hasAuthorship W3207681820A5049060308 @default.
• W3207681820 hasAuthorship W3207681820A5078451650 @default.
• W3207681820 hasBestOaLocation W32076818201 @default.
• W3207681820 hasConcept C121608353 @default.
• W3207681820 hasConcept C126322002 @default.
• W3207681820 hasConcept C141071460 @default.
• W3207681820 hasConcept C143998085 @default.
• W3207681820 hasConcept C167135981 @default.
• W3207681820 hasConcept C197934379 @default.
• W3207681820 hasConcept C2775999482 @default.
• W3207681820 hasConcept C2776232967 @default.
• W3207681820 hasConcept C2776256026 @default.
• W3207681820 hasConcept C2779422266 @default.
• W3207681820 hasConcept C2781182431 @default.
• W3207681820 hasConcept C71924100 @default.
• W3207681820 hasConceptScore W3207681820C121608353 @default.
• W3207681820 hasConceptScore W3207681820C126322002 @default.
• W3207681820 hasConceptScore W3207681820C141071460 @default.
• W3207681820 hasConceptScore W3207681820C143998085 @default.
• W3207681820 hasConceptScore W3207681820C167135981 @default.
• W3207681820 hasConceptScore W3207681820C197934379 @default.
• W3207681820 hasConceptScore W3207681820C2775999482 @default.
• W3207681820 hasConceptScore W3207681820C2776232967 @default.
• W3207681820 hasConceptScore W3207681820C2776256026 @default.
• W3207681820 hasConceptScore W3207681820C2779422266 @default.
• W3207681820 hasConceptScore W3207681820C2781182431 @default.
• W3207681820 hasConceptScore W3207681820C71924100 @default.
• W3207681820 hasIssue "10" @default.
• W3207681820 hasLocation W32076818201 @default.
• W3207681820 hasOpenAccess W3207681820 @default.
• W3207681820 hasPrimaryLocation W32076818201 @default.
• W3207681820 hasRelatedWork W1589805911 @default.
• W3207681820 hasRelatedWork W1592240224 @default.
• W3207681820 hasRelatedWork W1666785645 @default.
• W3207681820 hasRelatedWork W2166589505 @default.
• W3207681820 hasRelatedWork W2747108253 @default.
• W3207681820 hasRelatedWork W2763698474 @default.
• W3207681820 hasRelatedWork W2896790022 @default.
• W3207681820 hasRelatedWork W3201550227 @default.
• W3207681820 hasRelatedWork W4287874722 @default.
• W3207681820 hasRelatedWork W4386099802 @default.
• W3207681820 hasVolume "16" @default.
• W3207681820 isParatext "false" @default.
• W3207681820 isRetracted "false" @default.
• W3207681820 magId "3207681820" @default.
• W3207681820 workType "article" @default.